23,192 Shares in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Acquired by Proficio Capital Partners LLC

Proficio Capital Partners LLC purchased a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 23,192 shares of the company’s stock, valued at approximately $285,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Polar Asset Management Partners Inc. bought a new position in Mineralys Therapeutics during the 3rd quarter worth approximately $490,000. Jennison Associates LLC lifted its holdings in Mineralys Therapeutics by 55.4% in the 4th quarter. Jennison Associates LLC now owns 1,082,006 shares of the company’s stock worth $13,319,000 after buying an additional 385,726 shares during the period. Barclays PLC lifted its holdings in Mineralys Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 38,218 shares of the company’s stock worth $463,000 after buying an additional 28,208 shares during the period. Wellington Management Group LLP purchased a new stake in Mineralys Therapeutics in the 3rd quarter worth approximately $775,000. Finally, State Street Corp lifted its holdings in Mineralys Therapeutics by 4.0% in the 3rd quarter. State Street Corp now owns 483,766 shares of the company’s stock worth $5,858,000 after buying an additional 18,627 shares during the period. 84.46% of the stock is currently owned by institutional investors.

Insider Activity at Mineralys Therapeutics

In related news, CEO Jon Congleton sold 18,333 shares of the firm’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $9.06, for a total value of $166,096.98. Following the transaction, the chief executive officer now directly owns 877,608 shares of the company’s stock, valued at approximately $7,951,128.48. This trade represents a 2.05 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Adam Scott Levy sold 10,757 shares of the firm’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $9.10, for a total value of $97,888.70. Following the completion of the transaction, the chief financial officer now directly owns 226,097 shares in the company, valued at approximately $2,057,482.70. This represents a 4.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 33.24% of the stock is currently owned by insiders.

Mineralys Therapeutics Trading Down 4.4 %

NASDAQ MLYS opened at $14.30 on Wednesday. The stock’s fifty day moving average price is $10.35 and its 200-day moving average price is $11.90. Mineralys Therapeutics, Inc. has a 12 month low of $8.24 and a 12 month high of $18.29. The stock has a market cap of $712.65 million, a P/E ratio of -3.93 and a beta of 1.50.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.02. As a group, analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MLYS has been the subject of several research analyst reports. The Goldman Sachs Group dropped their price objective on Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Guggenheim reiterated a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, February 24th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Mineralys Therapeutics in a report on Monday.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.